Table 2.

Summary of diagnostic performance of cell-free and exosomal miRNA-based biomarker panel in the training and validation cohorts.

	Cohort	Signature	Control	Cancer	AUC (95% CI)	Accuracy (%) (95% CI)	PPV (%) (95% CI)	Sensitivity (%) (95% CI)	Specificity (%) (95% CI)	NPV (%) (95% CI)
All miRNA candidates	Training cohort (n=96)	cf-miRNA panel	34	62	0.90 (0.84-0.96)	80 (73-88)	96 (90-100)	73 (61-82)	94 (85-100)	65 (57-75)
		exo-miRNA panel	34	62	0.97 (0.94-1.00)	90 (83-96)	96 (92-100)	87 (77-95)	94 (85-100)	80 (70-91)
		combined signature	34	62	0.98 (0.97-1.00)	95 (90-99)	98 (95-100)	94 (87-98)	97 (91-100)	89 (80-97)
	Validation cohort (n=95)	cf-miRNA panel	33	62	0.83 (0.75-0.91)	77 (68-85)	85 (77-93)	79 (68-89)	73 (58-88)	65 (53-78)
		exo-miRNA panel	33	62	0.89 (0.82-0.95)	84 (77-92)	96 (91-100)	79 (68-89)	94 (85-100)	71 (61-82)
		combined signature	33	62	0.92 (0.87-0.97)	87 (80-94)	93 (87-98)	87 (77-95)	88 (76-97)	79 (68-90)
Reduced miRNA candidates	Training cohort (n=96)	cf-miRNA panel	34	62	0.90 (0.85-0.96)	84 (77-91)	91 (84-98)	84 (74-92)	85 (73-97)	74 (64-86)
		exo-miRNA panel	34	62	0.96 (0.92-0.99)	90 (83-96)	95 (90-100)	89 (81-95)	91 (82-100)	82 (71-92)
		combined signature	34	62	0.98 (0.95-1.00)	94 (89-98)	98 (95-100)	92 (85-98)	97 (91-100)	87 (78-97)
	Validation cohort (n=95)	cf-miRNA panel	33	62	0.84 (0.76-0.92)	80 (72-87)	92 (85-98)	76 (65-85)	88 (76-97)	66 (56-78)
		exo-miRNA panel	33	62	0.89 (0.82-0.96)	85 (78-92)	96 (91-100)	81 (69-90)	94 (85-100)	72 (62-83)
		combined signature	33	62	0.93 (0.88-0.98)	83 (76-91)	94 (88-100)	79 (69-89)	91 (79-100)	70 (60-81)

[miRNA: micro RNA; cf: cell-free miRNA; Exo: exosomal; AUC: area under the curve; PPV: positive predictive value; NPV: negative predictive value]